Shared on 03 Nov 25
Fair value Increased 2.33%Narrative Update: Bruker Analyst Price Target Increased Analysts have raised Bruker's fair value price target by approximately $1.09 to $47.82, citing improved ratings and updated market assessments, even as growth expectations have moderated slightly. Analyst Commentary Bullish Takeaways Bullish analysts note that the recent price target increase reflects greater confidence in Bruker’s ability to deliver stable financial results in the near term.
Shared on 06 Aug 25
Fair value Decreased 15%Renewed Biopharma Funding And Cost Savings Will Revitalize Markets
Bruker's consensus analyst price target has declined notably, primarily due to weaker revenue growth forecasts and a lower forward P/E multiple, resulting in a reduced fair value estimate of $46.73. What's in the News Bruker provided guidance for FY2025, projecting revenues of $3.43-$3.50 billion (2%-4% reported growth), driven mainly by M&A (3.5%) and FX tailwind (2.5%), but expects 2%-4% organic revenue decline; Q2 2025 revenue is projected to be approximately flat year-over-year at $795-$798 million (Key Developments).
Shared on 07 May 25
Fair value Decreased 11%Spatial Biology And Acquisitions Will Unlock Global Potential
Shared on 30 Apr 25
Spatial Biology And Acquisitions Will Unlock Global Potential
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
Fair value Decreased 3.11%Spatial Biology And Acquisitions Will Unlock Global Potential
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Decreased 4.16%Spatial Biology And Acquisitions Will Unlock Global Potential
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 5.36%Spatial Biology And Acquisitions Will Unlock Global Potential
AnalystConsensusTarget has decreased profit margin from 17.8% to 10.7% and increased future PE multiple from 20.6x to 32.7x.
Shared on 02 Apr 25
Fair value Increased 2.49%Spatial Biology And Acquisitions Will Unlock Global Potential
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Spatial Biology And Acquisitions Will Unlock Global Potential
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Increased 26%Spatial Biology And Acquisitions Will Unlock Global Potential
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 10 Mar 25
Fair value Decreased 1.54%Spatial Biology And Acquisitions Will Unlock Global Potential
AnalystConsensusTarget made no meaningful changes to valuation assumptions.